1200 – 1300 EST
James Kim, MBBCh, PgDip (Diabetes)
Patients with diabetes mellitus are at an increased risk of not only microvascular complications but also macrovascular complications including heart failure, coronary artery disease, and cerebrovascular events. Recent dedicated cardiovascular outcome trials have indicated increased cardiovascular benefit with certain glucagon-like pepid 1 receptor analogs (GLP-1 RAs) and sodium glucose cotransporter receptor inhibitors (SGLT-2i s), with nuances between specific agents in each class. With the plethora of trial data out there, clinicians would appreciate a simplified approach on which patient would benefit from what medication. We will be discussing a case-based approach to discuss a simplified clinical approach for optimal utilization of these medications.
At the conclusion of this session, the participant will be able to:
- Illustrate the increased risk of cardiovascular complications in patients with diabetes;
- Discuss the cardiovascular benefit of newer diabetes medications and the clinical relevance;
- Use a case-based management approach for implementing these medications in clinical practice.
Posted in: Saturday, October 17, 2020